Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4355756 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY4355756 Part A | EXPERIMENTAL | Single-ascending dose (SAD) of LY4355756 administered orally |
| LY4355756 Part B | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4355756 administered orally |
| LY4355756 Part C | EXPERIMENTAL | Single dose of LY4355756 administered orally in each of three study periods |
| LY4355756 + Midazolam Part D | EXPERIMENTAL | LY4355756 and midazolam co-administered orally |
| Midazolam Part D | EXPERIMENTAL | Midazolam administered orally |
| Name | Type | Description |
|---|---|---|
| LY4355756 | DRUG | Administered orally as capsule |
| Midazolam | DRUG | Administered orally as liquid |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, electrocardiogram (ECGs), and vital signs * Have a body mass index within the range 18.0-32.0 kilograms per square meter (kg/m²) (inclusive) * Individual...
LY4355756 is an investigational small molecule drug being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, with a single recruiting trial in healthy adult participants. The specific disease or condition it is intended to treat has not been disclosed.
LY4355756 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the drug in healthy participants.
LY4355756 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial is currently recruiting, and no trials for LY4355756 have been completed.
LY4355756 is being studied in one Phase 1 trial, NCT07765498, titled A Study of LY4355756 in Healthy Participants. The trial is recruiting in the United States, plans to enroll 123 participants aged 18 years and older, and is randomized, double-blind, and controlled.
Yes. The Phase 1 trial of LY4355756, NCT07765498, enrolls healthy adult volunteers rather than patients with a specific disease. It is a randomized, double-blind, controlled study with a planned enrollment of 123 participants, and it is currently recruiting in the United States.